Mechanisms of tumour escape from immune surveillance

Open access

Abstract

The progressive growth and spread of tumour cells in the form of metastases requires an interaction of healthy host cells, such as endothelial cells, fibroblasts, and other cells of mesenchymal origin with immune cells taking part in innate and adaptive responses within the tumour lesion and entire body. The host cells interact with tumour cells to create a dynamic tumour microenvironment, in which healthy cells can both positively and negatively influence the growth and spread of the tumour. The balance of cellular homeostasis and the effect of substances they secrete on the tumour microenvironment determine whether the tumour has a tendency to grow or disappear, and whether the cells remain within the lesion or are capable of metastasis to other regions of the body. Intercellular interactions also determine the tumour’s susceptibility to radiation or other types of cancer treatment. They may also be a rational explanation for differences in treatment outcomes, in which some metastases regress and others progress in response to the same treatment method.

1. Azuma M.: Role of the glucocorticoid-induced TNFR-related protein (GITR)-GITR ligand pathway in innate and adaptive immunity. Crit Rev Immunol 2010, 30, 547-557.

2. Baltz K.M., Krusch M., Bringmann A., Brossart P., Mayer F., Kloss M., Baessler T., Kumbier I., Peterfi A., Kupka S., Kroeber S., Menzel D, Radsak M.P., Rammensee H.G., Salih H.R.: Cancer immunoediting by GITR (glucocorticoid-induced TNFrelated protein) ligand in humans: NK cell/tumor cell interactions. FASEB J 2007, 21, 2442-2454.

3. Beatty G.L., Gladney W.L.: Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res 2015, 21, doi:

4. Beyer M., Schultze J.L.: Regulatory T cells: major players in the tumor microenvironment. Curr Pharm Des 2009, 15, 1879-1892.

5. Biller B.J., Elmslie R.E., Burnett R.C., Avery A.C., Dow S.W.: Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol 2007, 116, 69-78.

6. Biswas S.K., Lewis C.E.: NF-κB as a central regulator of macrophage function in tumors. J Leukoc Biol 2010, 88, 877-884.

7. Candolfi M., Curtin J.F., Yagiz K., Assi H., Wibowo M.K., Alzadeh G.E., Foulad D., Muhammad A.K.M.G., Salehi S., Keech N., Puntel M., Liu Ch., Sanderson N.R., Kroeger K.M., Dunn R., Martins G., Lowenstein P.R., Castro M.G.: B cells are critical to T-cell-mediated antitumor immunity induced by a combined immune-stimulatory/conditionally cytotoxic therapy for glioblastoma. Neoplasia 2011, 13, 947-960.

8. Cohen A.D., Schaer D.A., Liu C., Li Y., Hirschhorn- Cymmerman D., Kim S.C.: Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS ONE 2010, 5, e10436. doi:

9. Colotta F., Allavena P., Sica A., Garlanda C., Mantovani A.: Cancer related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis 2009, 30, 1073-1081.

10. Condamine T., Ramachandran I., Youn J., Gabrilovich D.I.: Regulation of tumor metastasis by myeloid-derived suppressor cells. Ann Rev Med 2015, 66, 97-110.

11. Contardi E., Palmisano G.L., Tazzari P.L., Martelli A.M., Falà F., Fabbi M., Kato T., Lucarelli E., Donati D., Polito L., Bolognesi A., Ricci F., Salvi S., Gargaglione V., Mantero S., Alberghini M., Ferrara G.B., Pistillo M.P.: CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer 2005, 117, 538-550.

12. Facciabene A., Motz G.T., Coukos G.: T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res 2012, 72, 2162-2171.

13. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., Zinzindohoué F., Bruneval P., Cugnenc P.H., Trajanoski Z., Fridman W.H., Pagès F.: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313, 1960-1964.

14. Garden O.A., Pinheiro D., Cunninghamb F.: All creatures great and small: regulatory T cells in mice, humans, dogs and other domestic animal species. Int Immunopharmacol 2011, 11, 576-588.

15. Gastman B.R., Johnson D.E., Whiteside T.L., Rabinowich H.: Tumor-induced apoptosis of T lymphocytes: elucidation of intracellular apoptotic events. Blood 2000, 95, 2015-2023.

16. Goldberg M.V., Drake C.G.: LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 2011, 344, 269-278.

17. Hayashi T., Horiuchi A., Sano K., Hiraoka N., Kasai M., Ichimura T., Sudo T., Tagawa Y., Nishimura R., Ishiko O., Kanai Y., Yaegashi N., Aburatani H., Shiozawa T., Konishi I.: Potential role of LMP2 as tumor-suppressor defines new targets for uterine leiomyosarcoma therapy. Sci Rep 2011, 1, 180, doi:

18. Huye L.E., Dotti G.: Designing T cells for cancer immunotherapy. Discov Med 2010, 47, 297-303.

19. Ichim T.E., Zhong Z., Kaushal S., Zheng X., Ren X., Hao X., Joyce J.A., Hanley H.H., Riordan N.H., Koropatnick J., Bogin V., Minev B.R., Min W., Tullis R.H.: Exosomes as a tumor immune escape mechanism: possible therapeutic implications. J Transl Med 2008, 6, 37 http://www.translationalmedicine.com/content/6/1/37.

20. Jagła M., Cichocka-Jarosz E.: Regulatory lymphocytes. Alerg Astma Immun 2007, 12, 22-29.

21. Ji H.B., Liao G., Faubion W.A., Abadia-Molina A.C., Cozzo C., Laroux F.S., Caton A., Terhorst C.: Cutting edge: the natural ligand for glucocorticoid-induced TNF receptor-related protein abrogates regulatory T cell suppression. J Immunol 2004, 172, 5823-5827.

22. Jiabei H., Ying H., Mingming H., Baolan L.: Development of PD-1/PD-L1 pathway in tumor immune microenvironment and treatment for non-small cell lung cancer. Sci Rep 2015, 5, doi:

23. Johnsen A.K., Templeton D.J., Sy M., Harding C.V.: Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis. J Immunol 1999, 163, 4224-4231.

24. Kaufman H.L., Disis M.L.: Immune system versus tumor: shifting the balance in favor of DCs and effective immunity. J Clin Invest 2004, 113, 664-667.

25. Kim P., Armstrong T., Song H., Wolpoe M., Weiss V., Manning E., Huang L., Murata S., Sgouros G., Emens L., Reilly R., Jaffe E.: Antibody association with HER-2/neu-targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 2008, 188, 1700-1711.

26. Kim R., Emi M., Tanabe K.: Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity. Immunology 2006, 119, 254-264.

27. Kumar V., Patel S., Tcyganov E., Gabrilovich D.I.: The nature of myeloid derived suppressor cells in the tumor microenvironment. Trends Immunol 2016, 37, 208-220.

28. Lewkowicz P., Lewkowicz N., Tchórzewski H.: CD4+CD25+ T regulatory cells in pathophysiology and therapy of immunological disorders. Postępy Hig Med Dośw 2005, 59, 371-376.

29. Lopez J., Tait S.W.G.: Mitochondrial apoptosis: killing cancer using the enemy within. Br J Cancer 2015, 112, 957-962.

30. Luczyński W., Krawczuk-Rybak M., Stasiak-Barmuta A.: Myeloid-derived suppressor cells - the new mechanism of immunosuppression in cancer. Postępy Hig Med Dośw 2008, 21, 18-22.

31. Luke J.L., Ott P.A.: PD-1 pathway inhibitors: The next generation of immunotherapy for advanced melanoma. Oncotarget 2015, 6, 3479-3492.

32. Maeda H., Shiraishi A.: TGF-beta contributes to the shift toward Th-2 type responses through direct and IL-10-mediated pathways in tumor-bearing mice. J Immunol 1996, 156, 73-78.

33. Mougiakakos D.: Regulatory T cells in colorectal cancer: from biology to prognostic relevance. Cancers 2011, 3, 1708-1731.

34. Nishikawa H., Sakaguchi S.: Regulatory T cells in tumor immunity. Int J Cancer 2010, 127, 759-767.

35. Oleinika K., Nibbs R.J., Graham G.J., Fraser A.R.: Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 2013, 171, 36-45.

36. Pinheiro D., Singh Y., Grant Ch.R., Appleton R.C., Sacchini F., Walker K.L.R., Chadbourne A.H., Palmer Ch.A., Armitage- Chan E., Thompson I., Williamson L., Cunningham F., Garden O.A.: Phenotypic and functional characterization of a CD4+CD25high FOXP3high regulatory T-cell population in the dog. Immunology 2010, 132, 111-122.

37. Poggi A., Massaro A.M., Negrini S., Contini P., Zocchi M.R.: Tumor-induced apoptosis of human IL-2-activated NK cells: role of natural cytotoxicity receptors. J Immunol 2005, 174, 2653-2660.

38. Poggi A., Zocchi M.R.: Mechanisms of tumor escape: role of tumor microenvironment in inducing apoptosis of cytolytic effector cells. Arch Immunol Ther Exp 2006, 54, 323-333.

39. Ryba M., Myśliwska J.: CD4+CD25+Foxp3+ T lymphocytes: naturally occurring T regulatory lymphocytes. Pediatr Endocrinol Diabetes Metab 2010, 16, 289-294.

40. Sato E., Olson S.H., Ahn J., Bundy B., Nishikawa H., Qian F., Jungbluth A.A., Frosina D., Gnjatic S., Ambrosone C., Kepner J., Odunsi T., Ritter G., Lele S., Chen Y.T., Ohtani H., Old L.J., Odunsi K.: Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005, 102, 18538-18543.

41. Sayers T.J.: Targeting the extrinsic apoptosis signaling pathway for cancer therapy. Cancer Immunol Immunother 2011, 60, 1173-1180.

42. Schreiber H., Wu T.H., Nachman J., Kast W.M.: Immunodominance and tumor escape. Semin Cancer Biol 2002, 12, 25-31.

43. Schreiber R.D., Old L.J., Smyth M.J.: Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011, 331, 1565-1570.

44. Shevach E.M., Stephens G.L.: The GITR-GITRL interaction: costimulation or contrasuppression of regulatory activity? Nature Rev Immunol 2006, 6, 613-618.

45. Sica A., Schioppa T., Mantovani A., Allavena P.: Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 2006, 42, 717-727.

46. Staveley-O’Carroll K., Sotomayor E., Montgomery J., Borello I., Hwang L., Fein S., Pardoll D., Levitsky H.: Induction of antigenspecific T cell anergy: an early event in the course of tumour progression. Proc Natl Acad Sci USA 1998, 95, 1179-1183.

47. Tiemessen M.M., Jagger A.L., Evans H.G., van Herwijnen M.J., John S., Taams L.S.:CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci USA 2007, 104, 19446-19451.

48. Upadhyay R., Hammerich L., Peng P., Brown B., Merad M., Brody J.D.: Lymphoma: immune evasion strategies. Cancers 2015, 7, 736-762.

49. Wesołowski R., Markovitz J., Carson W.E.: Myeloid derived suppressor cells-a new therapeutic target in the treatment of cancer. J Immunother Cancer 2013, 1, 10 http://www.immunotherapyofcancer.org/content/1/1/10.

50. Wolchok J.D., Chan T.A.: Cancer: Antitumour immunity gets a boost. Nature 2014, 515, 496-498.

51. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.L., Bettini M.L., Gravano D.M., Vogel P., Liu C.L., Tangsombatvisit S., Grosso J.F., Netto G., Smeltzer M.P., Chaux A., Utz P.J., Workman C.J., Pardoll D. M., Korman A.J., Drake C. G., Vignali D.A.A.: Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72, 917.

52. Xiao-Feng Qin F.: Dynamic behavior and function of Foxp3 regulatory T cells in tumor bearing host. Cell Mol Immunol 2009, 6, 3-13.

53. Yang Y.: Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest 2015, 125, 3335-3337.

54. Yang Z.Z., Ansell S.M.: The role of Treg cells in the cancer immunological response. Am J Immunol 2009, 5, 17-28.

55. Yuan A., Hsiao Y.J., Chen H.J., Chen H.W., Ho Ch. Ch., Chen Y.Y., Liu Y.Ch., Hong T.H., Yu S.L., Chen J.J.W., Yang P.Ch.: Opposite effects of M1 and M2 macrophage subtypes on lung cancer progression. Sci Rep 2015, 5, 1-12.

Journal of Veterinary Research

formerly Bulletin of the Veterinary Institute in Pulawy

Journal Information


IMPACT FACTOR Bull Vet Inst Pulawy 2016: 0.462

CiteScore 2016: 0.46

SCImago Journal Rank (SJR) 2015: 0.230
Source Normalized Impact per Paper (SNIP) 2015: 0.383

Cited By

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 445 445 41
PDF Downloads 189 189 31